See every side of every news story
Published loading...Updated

Alzamend Neuro Reports Annual 2025 Financial Results and Provides Update on Clinical Programs

Summary by Hastings Tribune
During the year ended April 30, 2025, net cash provided by financing activities was $10.4 millionStockholder equity of $4.0 million at April 30, 2025, including $3.9 million of cashIn May 2025, Alzamend dosed the first patient for the healthy human…

Bias Distribution

  • 100% of the sources are Center
100% Center

Factuality 

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Hastings Tribune broke the news in on Wednesday, July 23, 2025.
Sources are mostly out of (0)